Form 4: Cryo-Cell International Director Exercises Stock Options, Increases Common Stock Holdings
Insider Transaction Report
Cryo-Cell International Inc. Director Harold D. Berger exercised stock options to acquire 7,500 shares of common stock, increasing his direct beneficial ownership to 57,901 shares.
Summary
- Harold D. Berger, a Director of Cryo-Cell International Inc. (CCEL), acquired 7,500 shares of common stock through the exercise of a stock option.
- The transaction occurred on July 8, 2025, at an exercise price of $3.08 per share.
- Following this transaction, Mr. Berger's direct beneficial ownership of Cryo-Cell International Inc. common stock increased from 50,401 shares to 57,901 shares.
- The exercised stock option, which had an exercise price of $3.08 and was granted on July 9, 2015, expired on July 9, 2025, and is now no longer beneficially owned.
- Mr. Berger continues to hold several other stock options with various exercise prices and expiration dates, including 7,500 options at $7.53 (expiring 08/30/2029), 5,300 options at $7.74 (expiring 11/25/2029), 5,300 options at $7.85 (expiring 09/22/2030), 5,300 options at $12.63 (expiring 10/20/2031), 5,300 options at $6.50 (expiring 10/03/2032), 5,300 options at $4.90 (expiring 10/10/2033), and 5,300 options at $5.82 (expiring 10/29/2034).
Sentiment
Score: 6
Explanation: The exercise of stock options by a director, increasing their direct ownership, generally indicates confidence in the company's future prospects, though it is a routine compensation-related event.
Positives
- The exercise of stock options by a director increases their direct ownership in the company, which can be interpreted as a sign of confidence in the company's future performance.
- The exercise price of $3.08 suggests the option was in-the-money, indicating a potential gain for the director and reflecting positively on the stock's value relative to the option's grant price.
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive signal of management's belief in the company's value.
Key Dates
| Date | Description |
|---|---|
| 07/09/2015 | Grant date of the stock option exercised. |
| 08/30/2019 | Date exercisable for a stock option with an exercise price of $7.53, expiring 08/30/2029. |
| 11/25/2019 | Date exercisable for a stock option with an exercise price of $7.74, expiring 11/25/2029. |
| 09/22/2020 | Date exercisable for a stock option with an exercise price of $7.85, expiring 09/22/2030. |
| 10/20/2021 | Date exercisable for a stock option with an exercise price of $12.63, expiring 10/20/2031. |
| 10/03/2022 | Date exercisable for a stock option with an exercise price of $6.50, expiring 10/03/2032. |
| 10/10/2023 | Date exercisable for a stock option with an exercise price of $4.90, expiring 10/10/2033. |
| 10/29/2024 | Date exercisable for a stock option with an exercise price of $5.82, expiring 10/29/2034. |
| 07/08/2025 | Date of the reported transaction (stock option exercise). |
| 07/09/2025 | Expiration date of the exercised stock option. |
| 07/10/2025 | Date the Form 4 filing was signed. |
Keywords
CRYO CELL INTERNATIONAL INC, CCEL, Form 4, insider transaction, stock option exercise, beneficial ownership, Harold D. Berger, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.